Stock Price Movements, Share Repurchase Programs, and Financial Results - Research Report on Jazz Pharmaceuticals, Novo Nordisk, Teleflex, DENTSPLY International, and Fonar PR Newswire NEW YORK, November 20, 2013 NEW YORK, November 20, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Novo Nordisk A/S (ADR) (NYSE: NVO), Teleflex Incorporated (NYSE: TFX), DENTSPLY International Inc. (NASDAQ: XRAY), and Fonar Corporation (NASDAQ: FONR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Jazz Pharmaceuticals plc Research Report On November 15, 2013, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock declined 0.28%, ending the day at $108.39. Over the previous three trading sessions, shares of Jazz Pharmaceuticals gained 7.12%, outperforming the Nasdaq Composite which gained 1.68% during the same period. The Full Research Report on Jazz Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/5fe3_JAZZ Novo Nordisk A/S (ADR) Research Report On November 11, 2013, Novo Nordisk A/S (ADR) (Novo Nordisk) announced that on October 31, 2013, the Company initiated a share repurchase program pursuant to the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003, also known as the Safe Harbor rules. Novo Nordisk informed that this program is part of the overall share repurchase program of up to (Danish Krone) DKK14.0 billion to be executed during a 12-month period starting January 31, 2013. The Full Research Report on Novo Nordisk A/S (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/fee1_NVO Teleflex Incorporated Research Report On November 12, 2013, Teleflex Incorporated (Teleflex) announced that it was recently awarded a new agreement from Novation for its complete line of Arrow Intra-Aortic Balloon Catheters and Pumps. Teleflex further reported that the agreement, effective January 1, 2014, will provide more than 65,000 members by Novation with a variety of offerings from Teleflex, including the AutoCAT 2 WAVE Intra-Aortic Balloon Pump with the proprietary wave algorithm which detects the aortic valve closure point for each beat as it occurs. Teleflex informed that this technology enables accurate timing based on the individual characteristics of each heartbeat instantly, even during severe arrhythmia. Howard Miller, President, Cardiac Care Division of Teleflex, said, "We are proud to partner with Novation through the new agreement which provides hospital members the advanced Arrow® Intra-Aortic Balloon Technology from Teleflex for treating patients with severe cardiac events." The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9c7d_TFX DENTSPLY International Inc. Research Report On November 15, 2013, DENTSPLY International Inc.'s (DENTSPLY International) stock rose 0.14%, ending the day at $48.62. Over the previous three trading sessions, shares of DENTSPLY International gained 1.29% compared to the Nasdaq Composite which gained 1.68% during the same period. The Full Research Report on DENTSPLY International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/6b01_XRAY Fonar Corporation Research Report On November 15, 2013, Fonar Corporation (Fonar) reported its Q1 FY 2014 financial results (period ended September 30, 2013). The Company's total net revenues increased 77% YoY to $16.8 million during the quarter. Net income available to common stockholders was $2.3 million or $0.37 per diluted share in Q1 FY 2014 compared to net income available to common stockholders of $1.4 million or $0.22 per diluted share in Q1 FY 2013. Raymond V. Damadian M.D., President and Chairman of Fonar Corporation, said, "We had understood that the acquisition of HDM would be a significant source of profitability. This has been the case and the Company's diluted earnings per share available for the common stockholder for the 1st quarter of Fiscal 2014 increased 68% to $0.37 when compared to one year earlier. There are more reasons why this acquisition makes a lot of sense. By combining the resources of HMCA and HDM, we will enjoy the benefits of economies of scale, shared administrative and technical expertise and capabilities, and joint marketing strategies. HMCA's 11 STAND-UP® MRIs together with HDM's 12 form a network of 23 FONAR weight-bearing MRI scanners, the largest in the world as compared to the conventional essentially weightless MRI." The Full Research Report on Fonar Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/73cc_FONR EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com/ SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Stock Price Movements, Share Repurchase Programs, and Financial Results - Research Report on Jazz Pharmaceuticals, Novo Nordisk,
Press spacebar to pause and continue. Press esc to stop.